{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:08:21Z","timestamp":1788883701199,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374491"],"award-info":[{"award-number":["82374491"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cytogfr.2026.07.006","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:37:05Z","timestamp":1786549025000},"page":"125-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Molecular mechanisms of biologic and targeted synthetic antirheumatic drugs in rheumatoid arthritis"],"prefix":"10.1016","volume":"91","author":[{"given":"Longcan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengpeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengle","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingwen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cytogfr.2026.07.006_bib1","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s10067-023-06628-2","article-title":"Estimation of the global prevalence, incidence, years lived with disability of rheumatoid arthritis in 2019 and forecasted incidence in 2040: results from the Global Burden of Disease Study 2019","volume":"42","author":"Shi","year":"2023","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.006_bib2","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3390\/jcm12041291","article-title":"The Burden of Rheumatoid Arthritis: Findings from the 2019 Global Burden of Diseases Study and Forecasts for 2030 by Bayesian Age-Period-Cohort Analysis","volume":"12","author":"Cai","year":"2023","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.006_bib4","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2026.07.006_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152329","article-title":"Predicting best treatment in rheumatoid arthritis","volume":"64","author":"Lewis","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-60987-9","article-title":"Deep molecular profiling of synovial biopsies in the STRAP trial identifies signatures predictive of treatment response to biologic therapies in rheumatoid arthritis","volume":"16","author":"Lewis","year":"2025","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.07.006_bib7","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.30537","article-title":"Development of the anti\u2013citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis","volume":"63","author":"van de Stadt","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.07.006_bib8","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/rai2.12043","article-title":"Mechanism-driven strategies for prevention of rheumatoid arthritis","volume":"2","author":"Holers","year":"2022","journal-title":"Rheumatol. Autoimmun."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41584-020-0409-1","article-title":"PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets","volume":"16","author":"Curran","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib10","first-page":"18","article-title":"Circulating secretory IgA antibodies against cyclic citrullinated peptides in early rheumatoid arthritis associate with inflammatory activity and smoking","author":"Roos","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/art.30081","article-title":"Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll-like receptor 4 and Fc\u03b3 receptor","volume":"63","author":"Sokolove","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cytogfr.2026.07.006_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.709178","article-title":"New Insights From Single-Cell Sequencing Data: Synovial Fibroblasts and Synovial Macrophages in Rheumatoid Arthritis","volume":"12","author":"Cheng","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001949","article-title":"Role of synovial fibroblast subsets across synovial pathotypes in rheumatoid arthritis: a deconvolution analysis","volume":"8","author":"Micheroli","year":"2022","journal-title":"RMD Open."},{"issue":"7760","key":"10.1016\/j.cytogfr.2026.07.006_bib14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nat."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.07.006_bib15","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat. Med."},{"issue":"39","key":"10.1016\/j.cytogfr.2026.07.006_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj1252","article-title":"Loss of synovial tissue macrophage homeostasis precedes rheumatoid arthritis clinical onset","volume":"10","author":"Hanlon","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.cytogfr.2026.07.006_bib17","doi-asserted-by":"crossref","unstructured":"De Lima J., Boutet M.A., Bortolotti O., Ch\u00e9peaux L.A., Glasson Y., Dum\u00e9 A.S., et al. Spatial mapping of rheumatoid arthritis synovial niches reveals specific macrophage networks associated with response to therapy. openRxiv; 2023. Available from: http:\/\/dx.doi.org\/10.1101\/2023.10.20.563040.","DOI":"10.1101\/2023.10.20.563040"},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.006_bib18","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/annrheumdis-2012-202765","article-title":"Antibodies from patients with rheumatoid arthritis target citrullinated histone 4 contained in neutrophils extracellular traps","volume":"73","author":"Pratesi","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"7639","key":"10.1016\/j.cytogfr.2026.07.006_bib19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib20","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-024-00802-1","article-title":"Single-cell characterisation of tissue homing CD4\u2009+\u2009and CD8\u2009+\u2009T cell clones in immune-mediated refractory arthritis","volume":"30","author":"Bhattacharya","year":"2024","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.006_bib22","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/pro.3519","article-title":"The molecular details of cytokine signaling via the JAK\/STAT pathway","volume":"27","author":"Morris","year":"2018","journal-title":"Protein Sci."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.006_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.07.006_bib24","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/ng.874","article-title":"A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis","volume":"43","author":"Matmati","year":"2011","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.006_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/gm444","article-title":"An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype","volume":"5","author":"Whitaker","year":"2013","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-021-02460-6","article-title":"Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability","volume":"22","author":"Ge","year":"2021","journal-title":"Genome Biol."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.07.006_bib27","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1172\/JCI25265","article-title":"BLyS and APRIL in rheumatoid arthritis","volume":"115","author":"Seyler","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.07.006_bib28","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: A comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/JLB.2MR0120-510R","article-title":"Distinct modes of TNF signaling through its two receptors in health and disease","volume":"107","author":"Atretkhany","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.07.006_bib30","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41584-021-00639-6","article-title":"Insights into the biology and therapeutic implications of TNF and regulatory T cells","volume":"17","author":"Salomon","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cytogfr.2026.07.006_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2019.00091","article-title":"TNFR1 and TNFR2 in the Control of the Life and Death Balance of Macrophages","volume":"7","author":"Wajant","year":"2019","journal-title":"Front. Cell. Dev. Biol."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.07.006_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: a road to inflammation","volume":"23","author":"van Loo","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.006_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/ni1576","article-title":"TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon\u2013response genes","volume":"9","author":"Yarilina","year":"2008","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/art.38871","article-title":"Prolonged Tumor Necrosis Factor \u03b1 Primes Fibroblast-like Synoviocytes in a Gene-Specific Manner by Altering Chromatin","volume":"67","author":"Sohn","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.07.006_bib35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2019.06.005","article-title":"The Cytokine TNF Promotes Transcription Factor SREBP Activity and Binding to Inflammatory Genes to Activate Macrophages and Limit Tissue Repair","volume":"51","author":"Kusnadi","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.006_bib36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/rheumatology\/keq031","article-title":"Transmembrane TNF-: structure, function and interaction with anti-TNF agents","volume":"49","author":"Horiuchi","year":"2010","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.cytogfr.2026.07.006_bib37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect. Dis."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.006_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","article-title":"Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment","volume":"13","author":"Kalden","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"14","key":"10.1016\/j.cytogfr.2026.07.006_bib39","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cytogfr.2026.07.006_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00845","article-title":"A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNF\u03b1-Blockade in Rheumatoid Arthritis Patients","volume":"11","author":"Nerviani","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2026.07.006_bib41","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.07.006_bib43","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cytogfr.2015.07.004","article-title":"Interleukin-6: Biology, signaling and strategies of blockade","volume":"26","author":"Schaper","year":"2015","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.07.006_bib44","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta - Mol. Cell. Res."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.006_bib45","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.006_bib46","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib47","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nri2093","article-title":"SOCS proteins, cytokine signalling and immune regulation","volume":"7","author":"Yoshimura","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.006_bib48","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1084\/jem.20020619","article-title":"A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis","volume":"196","author":"Atsumi","year":"2002","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.006_bib49","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.006_bib50","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"9877","key":"10.1016\/j.cytogfr.2026.07.006_bib52","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial","volume":"381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cytogfr.2026.07.006_bib53","first-page":"16","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","author":"Dennis","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib54","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.07.006_bib55","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: From Mechanism to Therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.006_bib56","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41573-020-0081-9","article-title":"Targeting co-stimulatory molecules in autoimmune disease","volume":"19","author":"Edner","year":"2020","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"6029","key":"10.1016\/j.cytogfr.2026.07.006_bib57","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib58","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.006_bib59","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib60","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"25","key":"10.1016\/j.cytogfr.2026.07.006_bib61","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-Cell\u2013Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.006_bib62","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41584-022-00786-4","article-title":"From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis","volume":"18","author":"Scherer","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.006_bib63","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.07.006_bib64","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/ard.2006.060772","article-title":"Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production","volume":"66","author":"Lavie","year":"2007","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.006_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0060001","article-title":"Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium","volume":"6","author":"Humby","year":"2009","journal-title":"PLoS Med."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.006_bib66","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169754","article-title":"Autoimmunity to stromal-derived autoantigens in rheumatoid ectopic germinal centers exacerbates arthritis and affects clinical response","volume":"134","author":"Corsiero","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.07.006_bib67","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/ard-2022-223396","article-title":"Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritis","volume":"82","author":"Kugler","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"10271","key":"10.1016\/j.cytogfr.2026.07.006_bib68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib69","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1534-5807(02)00369-6","article-title":"Induction and Activation of the Transcription Factor NFATc1 (NFAT2) Integrate RANKL Signaling in Terminal Differentiation of Osteoclasts","volume":"3","author":"Takayanagi","year":"2002","journal-title":"Dev. Cell."},{"issue":"9","key":"10.1016\/j.cytogfr.2026.07.006_bib70","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20051150","article-title":"Autoamplification of NFATc1 expression determines its essential role in bone homeostasis","volume":"202","author":"Asagiri","year":"2005","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.006_bib71","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.07.006_bib72","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P","article-title":"Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor","volume":"43","author":"Gravallese","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.07.006_bib73","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/rheumatology\/ken363","article-title":"IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17","volume":"47","author":"Hashizume","year":"2008","journal-title":"Rheumatol."},{"key":"10.1016\/j.cytogfr.2026.07.006_bib74","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0084-3873(09)79332-0","article-title":"Denosumab Treatment Effects on Structural Damage, Bone Mineral Density, and Bone Turnover in Rheumatoid Arthritis: A Twelve-Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial","volume":"2009","author":"Cotter","year":"2009","journal-title":"Yearb. Med."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.006_bib75","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2010.132852","article-title":"Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression","volume":"69","author":"Heiland","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.07.006_bib76","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3390\/life15111737","article-title":"Targeting GM-CSF in Rheumatoid Arthritis: Advances in Cytokine-Directed Immunotherapy and Clinical Implications","volume":"15","author":"Garc\u00eda-Dom\u00ednguez","year":"2025","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.07.006_bib77","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cell.2008.05.053","article-title":"The Structure of the GM-CSF Receptor Complex Reveals a Distinct Mode of Cytokine Receptor Activation","volume":"134","author":"Hansen","year":"2008","journal-title":"Cell."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.07.006_bib78","doi-asserted-by":"crossref","first-page":"e677","DOI":"10.1016\/S2665-9913(20)30229-0","article-title":"Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study","volume":"2","author":"Buckley","year":"2020","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.07.006_bib79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1189\/jlb.71.3.511","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte\/macrophage differentiation","volume":"71","author":"Lehtonen","year":"2002","journal-title":"J. Leukoc. Biol."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib80","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0002-9440(10)63068-4","article-title":"Cathepsin K Is a Critical Protease in Synovial Fibroblast-Mediated Collagen Degradation","volume":"159","author":"Hou","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cytogfr.2026.07.006_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2016.00184","article-title":"Hypoxia-Inducible Factor (HIF) as a Target for Novel Therapies in Rheumatoid Arthritis","volume":"7","author":"Hua","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cytogfr.2026.07.006_bib82","series-title":"Cochrane Database of Systematic Reviews","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","author":"Singh","year":"2009"},{"issue":"9","key":"10.1016\/j.cytogfr.2026.07.006_bib83","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.07.006_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2024.101941","article-title":"TNFR2 signalling in inflammatory diseases","volume":"38","author":"Williams","year":"2024","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.cytogfr.2026.07.006_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104840","article-title":"Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors","volume":"97","author":"Jensen","year":"2023","journal-title":"eBioMedicine"},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.006_bib86","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"S1","key":"10.1016\/j.cytogfr.2026.07.006_bib87","first-page":"14","article-title":"Evidence for synovial fibroblasts spreading rheumatoid arthritis","author":"M\u00fcller-Ladner","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cytogfr.2026.07.006_bib88","doi-asserted-by":"crossref","unstructured":"Wang L., Huang S., Li S., Li M., Shi J., Bai W., et al. Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I\/II Study Drug Des Devel Ther. 2019;Volume 13:4331\u201340. Available from: http:\/\/dx.doi.org\/10.2147\/dddt.s225613.","DOI":"10.2147\/DDDT.S225613"},{"issue":"9","key":"10.1016\/j.cytogfr.2026.07.006_bib89","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/annrheumdis-2018-214783","article-title":"TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis","volume":"78","author":"Loh","year":"2019","journal-title":"Ann. Rheum. Dis."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:31:57Z","timestamp":1788881517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610126000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":89,"alternative-id":["S1359610126000584"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.07.006","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular mechanisms of biologic and targeted synthetic antirheumatic drugs in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}